No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 4, 2007, Pages 310-316

  Kwak, Cheol ^a   Park, Yong Hyun ^a   Jeong, Chang Wook ^a   Lee, Sang Eun ^b   Ku, Ja Hyeon ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Immunotherapy; Metastasectomy; Metastasis; Nephrectomy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CALCULATION; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 34447098702     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.08.022     Document Type: Article

References (30)

1. Rabinovitch R.A., Zelefsky M.J., Gaynor J.J., et al. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol 12 (1994) 206-212
2. Dekernion J.B., Ramming K.P., and Smith R.B. The natural history of metastatic renal cell carcinoma: A computer analysis. J Urol 120 (1978) 148-152
3. Vogelzang N.J., and Stadler W.M. Kidney cancer. Lancet 352 (1998) 1691-1696
4. Jones M., Philip T., Palmer P., et al. The impact of interleukin-2 on survival in renal cancer: A multivariate analysis. Cancer Biother 8 (1993) 275-288
5. Atzpodien J., Kirchner H., Hanninen E.L., et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29A Suppl 5 (1993) S6-S8
6. Elias L., Binder M., Mangalik A., et al. Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma. Am J Clin Oncol 22 (1999) 156-161
7. Hofmockel G., Langer W., Theiss M., et al. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 156 (1996) 18-21
8. Atzpodien J., Hoffmann R., Franzke M., et al. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95 (2002) 1045-1050
9. van Herpen C.M., Jansen R.L., Kruit W.H., et al., Dutch Immunotherapy Working Party. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: A multicenter phase II study. Br J Cancer 82 (2000) 772-776
10. Elias L., Lew D., Figlin R.A., et al. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma. Cancer 89 (2000) 597-603
11. Joffe J.K., Banks R.E., Forbes M.A., et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: Clinical data and laboratory evidence of protease activation. Br J Urol 77 (1996) 638-649
12. O'Brien M.F., Rea D., Rogers E., et al. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: The all Ireland experience. Eur Urol 45 (2004) 613-618
13. Sengupta S., Leibovich B.C., Blute M.L., et al. Surgery for metastatic renal cell cancer. World J Urol 23 (2005) 155-160
14. Kuczyk M.A., Anastasiadis A.G., Zimmermann R., et al. Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer. BJU Int 96 (2005) 721-727
15. Kavolius J.P., Mastorakos D.P., Pavlovich C., et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 16 (1998) 2261-2266
16. Kozlowski J.M. Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol Clin North Am 21 (1994) 601-624
17. van der Poel H.G., Roukema J.A., Horenblas S., et al. Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis. Eur Urol 35 (1999) 1972-03
18. Itano N.B., Blute M.L., Spotts B., et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164 (2000) 322-325
19. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 358 (2001) 966-970
20. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
21. Spencer W.F., Linehan W.M., Walther M.M., et al. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: A pilot study. J Urol 147 (1992) 24-30
22. Robertson C.N., Linehan W.M., Pass H.I., et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 144 (1990) 614-617
23. Sella A., Swanson D.A., Ro J.Y., et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 149 (1993) 19-21
24. Wagner J.R., Walther M.M., Linehan W.M., et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 162 (1999) 43-45
25. Rackley R., Novick A., Klein E., et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 152 (1994) 1399-1403
26. Robertson C.N., Linehan W.M., Pass H.I., et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 144 (1990) 614-617
27. Sherry R.M., Pass H.I., Rosenberg S.A., et al. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 69 (1992) 1850-1855
28. Stadler W.M. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104 (2005) 2323-2333
29. Eto M., and Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol 11 (2006) 209-213
30. Nathan P., Chao D., Brock C., et al. The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer 94 (2006) 1217-1220